In osteosarcoma, combination of β-elemene and paclitaxel inhibited bone neoplasm growth via downregulating ADGRA2, suggesting a potential role for ADGRA2 in therapy response [75]. The gene discussed is ADGRA2; the disease is bone neoplasm.